# BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT02684357** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 577 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** risankizumab
- **DRUG:** ustekinumab
- **DRUG:** placebo for risankizumab
- **DRUG:** placebo for ustekinumab

## Key facts

- **NCT ID:** NCT02684357
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-12
- **Final completion:** 2017-09
- **Target enrollment:** 577 (ACTUAL)
- **Last updated:** 2021-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684357, "BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02684357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*